This company listing is no longer active
De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!
ProSomnus Inkomsten in het verleden
Verleden criteriumcontroles 0/6
ProSomnus's earnings have been declining at an average annual rate of -44.2%, while the Medical Equipment industry saw earnings growing at 8.3% annually. Revenues have been growing at an average rate of 33.7% per year.
Belangrijke informatie
-44.2%
Groei van de winst
-20.5%
Groei van de winst per aandeel
| Medical Equipment Groei van de industrie | 8.9% |
| Inkomstengroei | 33.7% |
| Rendement op eigen vermogen | n/a |
| Nettomarge | -94.9% |
| Laatste winstupdate | 30 Jun 2024 |
Recente prestatie-updates uit het verleden
Opbrengsten en kosten
Hoe ProSomnus geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.
Inkomsten en omzetgeschiedenis
| Datum | Inkomsten | Inkomsten | G+A Uitgaven | R&D-uitgaven |
|---|---|---|---|---|
| 30 Jun 24 | 31 | -30 | 24 | 5 |
| 31 Mar 24 | 29 | -14 | 27 | 5 |
| 31 Dec 23 | 28 | -24 | 28 | 5 |
| 30 Sep 23 | 26 | -15 | 29 | 5 |
| 30 Jun 23 | 24 | -7 | 26 | 4 |
| 31 Mar 23 | 21 | -11 | 21 | 3 |
| 31 Dec 22 | 19 | -7 | 19 | 3 |
| 30 Sep 22 | 18 | -12 | 14 | 2 |
| 30 Jun 22 | 17 | -9 | 12 | 2 |
| 31 Mar 22 | 15 | -8 | 11 | 2 |
| 31 Dec 21 | 14 | -6 | 10 | 2 |
| 31 Dec 20 | 8 | -6 | 7 | 1 |
Kwaliteitswinsten: OSAP.Q is currently unprofitable.
Groeiende winstmarge: OSAP.Q is currently unprofitable.
Analyse vrije kasstroom versus winst
Analyse van de winstgroei in het verleden
Winsttrend: OSAP.Q is unprofitable, and losses have increased over the past 5 years at a rate of 44.2% per year.
Versnelling van de groei: Unable to compare OSAP.Q's earnings growth over the past year to its 5-year average as it is currently unprofitable
Winst versus industrie: OSAP.Q is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (3.9%).
Rendement op eigen vermogen
Hoge ROE: OSAP.Q's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.